Brief: Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Acadia Pharmaceuticals

24/09/2025 12:05

Sept 24 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O:

ACADIA PHARMACEUTICALS ANNOUNCES PHASE 3 COMPASS PWS TRIAL OF INTRANASAL CARBETOCIN (ACP-101) FOR HYPERPHAGIA IN PRADER-WILLI SYNDROME DID NOT MEET PRIMARY ENDPOINT

ACADIA PHARMACEUTICALS INC - PHASE 3 TRIAL DID NOT MEET PRIMARY ENDPOINT

ACADIA PHARMACEUTICALS INC - INTRANASAL CARBETOCIN SHOWED NO SIGNIFICANT IMPROVEMENT OVER PLACEBO

ACADIA PHARMACEUTICALS INC - INTRANASAL CARBETOCIN SHOWED LOW RATE OF ADVERSE EVENTS

ACADIA PHARMACEUTICALS INC: SAFETY AND TOLERABILITY PROFILE OF INTRANASAL CARBETOCIN WAS CONSISTENT WITH PREVIOUS CLINICAL TRIALS

Source text: ID:nBw47KWTJa

Further company coverage: ACAD.O

 ((Reuters.Briefs@thomsonreuters.com;))